Attenuation of Aβ deposition in the entorhinal cortex of normal elderly individuals associated with tobacco smoking

Neuropathology and Applied Neurobiology

Volumn 31, Issue 5, 2005, Pages 522-535

  Court, J A ^a   Johnson, M ^a   Religa, D ^b,c   Keverne, J ^a   Kalaria, R ^a   Jaros, E ^a   McKeith, I G ^a   Perry, R ^a   Naslund, J ^b   Perry, E K ^a  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

^c MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

amyloidosis; Ex smokers; Nicotine; Non smokers; Smokers; Tau; Vascular amyloid; Vascular markers

Indexed keywords

ALPHA ACTIN; AMYLOID BETA PROTEIN; BIOCHEMICAL MARKER; CATION CHANNEL; COLLAGEN TYPE 4; FORMIC ACID; GLUCOSE TRANSPORTER 1; NICOTINE; PHOSPHATE BUFFERED SALINE; NICOTINIC RECEPTOR;

AGING; ALZHEIMER DISEASE; AMYLOIDOSIS; ARTICLE; CIGARETTE SMOKING; ENTORHINAL CORTEX; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; LEPTOMENINX; LONG TERM EXPOSURE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; AGE; AGED; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMAGE PROCESSING; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; PATHOLOGY; SEX DIFFERENCE; SMOKING; VASCULARIZATION;

AGE FACTORS; AGED; AGED, 80 AND OVER; AMYLOID BETA-PROTEIN; ENTORHINAL CORTEX; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MALE; RECEPTORS, NICOTINIC; SEX FACTORS; SMOKING;

EID: 25144468322     PISSN: 03051846     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2990.2005.00674.x     Document Type: Article

References (107)

1. Paterson D, Nordberg A. Neuronal nicotinic receptors in the human brain. Prog Neurobiol 2000; 61: 75-111
2. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci 1997; 20: 92-8
3. Jones S, Sudweeks S, Yakel JL. Nicotinic receptors in the brain: correlating physiology with function. Trends Neurosci 1999; 22: 555-61
4. Court JA, Martin-Ruiz C, Graham A, Perry E. Nicotinic receptors in human brain: topography and pathology. J Chem Neuroanat 2000; 20: 281-98
5. Breese CR, Adams C, Logel J, Drebing C, Rollins Y, Barnhart M, Sullivan B, Demasters BK, Freedman R, Leonard S. Comparison of the regional expression of nicotinic acetylcholine receptor alpha7 mRNA and [125I]-alpha-bungarotoxin binding in human postmortem brain. J Comp Neurol 1997; 387: 385-98
6. Court J, Spurden D, Lloyd S, McKeith I, Ballard C, Cairns N, Kerwin R, Perry R, Perry E. Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus. J Neurochem 1999; 73: 1590-7
7. Hellstrom-Lindahl E, Court JA. Nicotinic acetylcholine receptors during prenatal development and brain pathology in human aging. Behav Brain Res 2000; 113: 59-68
8. Court JA, Lloyd S, Johnson M, Griffiths M, Birdsall NJ, Piggott MA, Oakley AE, Ince PG, Perry EK, Perry RH. Nicotinic and muscarinic cholinergic receptor binding in the human hippocampal formation during development and aging. Brain Res Dev Brain Res 1997; 101: 93-105
9. Court J, Martin-Ruiz C, Piggott M, Spurden D, Griffiths M, Perry E. Nicotinic receptor abnormalities in Alzheimer's disease. Biol Psychiatry 2001; 49: 175-84
10. Graham AJ, Martin-Ruiz CM, Teaktong T, Ray MA, Court JA. Human brain nicotinic receptors their distribution and participation in neuropsychiatric disorders. Curr Drug Targets CNS Neurol Disord 2002; 1: 387-97
11. Perry EK, Perry RH, Smith CJ, Purohit D, Bonham J, Dick DJ, Candy JM, Edwardson JA, Fairbairn AF. Cholinergic receptors in cognitive disorders. Can J Neurol Sci 1986; 13: 521-7
12. Martin-Ruiz CM, Court JA, Molnar E, Lee M, Gotti C, Mamalaki A, Tsouloufis T, Tzartos S, Ballard C, Perry RH, Perry EK. Alpha4 but not alpha 3 and alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. J Neurochem 1999; 73: 1635-40
13. Guan ZZ, Zhang X, Ravid R, Nordberg A. Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. J Neurochem 2000; 74: 237-43
14. Burghaus L, Schutz U, Krempel U, de Vos RA, Jansen Steur EN, Wevers A, Lindstrom J, Schroder H. Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients. Brain Res Mol Brain Res 2000; 76: 385-8
15. Sabbagh MN, Reid RT, Corey-Bloom J, Rao TS, Hansen LA, Alford M, Masliah E, Adern A, Lloyd GK, Thai LJ. Correlation of nicotinic binding with neurochemical markers in Alzheimer's disease. J Neural Transm 1998; 105: 709-17
16. Zanardi A, Leo G, Biagini G, Zoli M. Nicotine and neurodegeneration in ageing. Toxicol Lett 2002; 127: 207-15
17. Kihara T, Shimohama S, Sawada H, Kimura J, Kume T, Kochiyama H, Maeda T, Akaike A. Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity. Ann Neurol 1997; 42: 159-63
18. Kihara T, Shimohama S, Urushitani M, Sawada H, Kimura J, Kume T, Maeda T, Akaike A. Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity. Brain Res 1998; 792: 331-4
19. Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Shibasaki H, Kume T, Akaike A. Alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta-amyloid-induced neurotoxicity. J Biol Chem 2001; 276: 13541-6
20. Seo J, Kimn S, Kim H, Park CH, Jeong S, Lee J, Choi SH, Chang K, Rah J, Koo J, Kim E, Suh Y. Effects of nicotine on APP secretion and Abeta- or CT(105)-induced toxicity. Biol Psychiatry 2001; 49: 240-7
21. Gahring LC, Meyer EL, Rogers SW. Nicotine-induced neuroprotection against N-methyl-D-aspartic acid or beta-amyloid peptide occur through independent mechanisms distinguished by pro-inflammatory cytokines. J Neurochem 2003; 87: 1125-36
22. Liu Q, Kawai H, Berg DK. Beta-Amyloid peptide blocks the response of alpha 7-containing nicotinic receptors on hippocampal neurons. Proc Natl Acad Sci USA 2001; 98: 4734-9
23. Hellstrom-Lindahl E, Court J, Keverne J, Svedberg M, Lee M, Marutle A, Thomas A, Perry E, Bednar I, Nordberg A. Nicotine reduces Abeta in the brain and cerebral vessels of APPsw mice. Eur J Neurosci 2004; 19: 2703-10
24. Utsuki T, Shoaib M, Holloway HW, Ingram DK, Wallace WC, Haroutunian V, Sambamurti K, Lahiri DK, Greig NH. Nicotine lowers the secretion of the Alzheimer's amyloid beta-protein precursor that contains amyloid beta-peptide in rat. J Ahheimers Dis 2002; 4: 405-15
25. Zoli M, Picciotto MR, Ferrari R, Cocchi D, Changeux JP. Increased neurodegeneration during ageing in mice lacking high-affinity nicotine receptors. EMBO J 1999; 18: 1235-44
26. Lee PN. Smoking and Alzheimer's disease: a review of the epidemiological evidence. Neuroepidemiology 1994; 13: 131-44
27. Ott A, Slooter AJ, Hofman A, van Harskamp F, Witteman JC, Van Broeckhoven C, van Duijn CM, Breteler MM. Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study. Lancet 1998; 351: 1840-3
28. van Duijn CM, Havekes LM, Broeckhoven CV, de Knijff P, Hofman A. Apolipoprotein E genotype and association between smoking and early onset Alzheimer's disease. BMJ 1995; 310: 627-31
29. Merchant C, Tang MX, Albert S, Manly J, Stern Y, Mayeux R. The influence of smoking on the risk of Alzheimer's disease. Neurology 1999; 52: 1408-12
30. Wald NJ, Hackshaw AK. Cigarette smoking: an epidemiological overview. Br Med Bull 1996; 52: 3-11
31. Kalaria RN. Cerebrovascular degeneration is related to amyloid-beta protein deposition in Alzheimer's disease. Ann NY Acad Sci 1997; 826: 263-71
32. Kalaria R, Skoog I. Overlap with Alzheimer's disease. In Vascular Cognitive Impairment. Eds T Erkinjuntti, S Gauthier. London: Martin Dunitz Publishers, 2002; 145-66.
33. Purohit DP, Perl DP, Haroutunian V, Powchik P, Davidson M, Davis KL. Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: a postmortem neuropathologic study of 100 cases. Arch Gen Psychiatry 1998; 55: 205-11
34. Powchik P, Davidson M, Haroutunian V, Gabriel SM, Purohit DP, Perl DP, Harvey PD, Davis KL. Postmortem studies in schizophrenia. Schizophr Bull 1998; 24: 325-41
35. Dwork AJ, Susser ES, Keilp J, Waniek C, Liu D, Kaufman M, Zemishlany Z, Prohovnik I. Senile degeneration and cognitive impairment in chronic schizophrenia. Am J Psychiatry 1998; 155: 1536-43
36. Adler LE, Olincy A, Waldo M, Harris JG, Griffith J, Stevens K, Flach K, Nagamoto H, Bickford P, Leonard S, Freedman R. Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull 1998; 24: 189-202
37. Baldessarini RJ, Hegarty JD, Bird ED, Benes FM. Meta-analysis of postmortem studies of Alzheimer's disease-like neuropathology in schizophrenia. Am J Psychiatry 1997; 154: 861-3
38. Ulrich J, Johannson-Locher G, Seiler WO, Stahelin HB. Does smoking protect from Alzheimer's disease? Alzheimer-type changes in 301 unselected brains from patients with known smoking history. Acta Neuropathol 1997; 94: 450-4
39. Perry E, Martin-Ruiz C, Lee M, Griffiths M, Johnson M, Piggott M, Haroutunian V, Buxbaum JD, Nasland J, Davis K, Gotti C, Clementi F, Tzartos S, Cohen O, Soreq H, Jaros E, Perry R, Ballard C, McKeith I, Court J. Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Eur J Pharmacol 2000; 393: 215-22
40. Hellstrom-Lindahl E, Mousavi M, Ravid R, Nordberg A. Reduced levels of Abeta 40 and Abeta 42 in brains of smoking controls and Alzheimer's patients. Neurobiol Dis 2004; 15: 351-60
41. Teaktong T, Graham AJ, Johnson M, Court JA, Perry EK. Selective changes in nicotinic acetylcholine receptor subtypes related to tobacco smoking: an immunohistochemical study. Neuropathol Appl Neurobiol 2004; 30: 243-54
42. Kalaria RN, Homayoun P, Whitehouse PJ. Nicotinic cholinergic receptors associated with mammalian cerebral vessels. J Auton Nerv Syst 1994; 49 (Suppl.): S3-7
43. Macklin KD, Maus ADJ, Pereira EFR, Albuquerque EX, Conti-Fine BM. Human vascular endothelial cells express functional nicotinic acetylcholine receptors. J Pharmacol Exp Ther 1998; 287: 435-9
44. Hans FJ, Wei L, Bereczki D, Acuff V, Demaro J, Chen JL, Otsuka T, Patlak C, Fenstermacher J. Nicotine increases microvascular blood flow and flow velocity in three groups of brain areas. Am J Physiol 1993; 265: H2142-50
45. Iida M, Iida H, Dohi S, Takenaka M, Fujiwara H. Mechanisms underlying cerebrovascular effects of cigarette smoking in rats in vivo. Stroke 1998; 29: 1656-65
46. Meyer JS, Shirai T, Muramatsu K, Mortel KF. Effects of chronic cigarette smoking and abstention on cerebral perfusion among neurologically normal volunteers. In Brain Imaging of Nicotine and Tobacco Smoking. Ed. EF Domino. Ann Arbor, MI: NPP Books, 1995; 137-51
47. Wang L, Kittaka M, Sun N, Schreiber SS, Zlokovic BC. Chronic nicotine treatment enhances focal ischemic brain injury and depletes free pool of brain microvascular tissue plasminogen activator in rats. J Cereb Blood Flow Metab 1997; 17: 136-46
48. Kalaria RN, Cohen DL, Greenberg BD, Savage MJ, Bogdanovic NE, Winblad B, Lannfelt L, Adem A. Abundance of the longer A beta 42 in neocortical and cerebrovascular amyloid beta deposits in Swedish familial Alzheimer's disease and Down's syndrome. Neuroreport 1996; 7: 1377-81
49. Mufson EJ, Chen E-Y, Cochran EJ, Beckett LA, Bennett DA, Kordower JH. Entorhinal cortex β-amyloid load in individuals with mild cognitive impairment. Exp Neurol 1999; 158: 469-90
50. Arriagada PV, Marzloff K, Hyman BT. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology 1992; 42: 1681-8
51. 3H]nicotine binding in human cortex: relative abundance in subicular complex. J Chem Neuroanat 1992; 5: 399-405
52. Mochizuki T, Villemagne V, Scheffel U, Dannais R, Finley P, Zhan Y, Wagner H, Musachio J. Nicotine induced up-regulation of nicotinic receptors in CD-1 mice demonstrated with an in vivo radiotracer: gender differences. Synapse 1998; 30: 116-18
53. Weller RO, Nicoll JA. Cerebral amyloid angiopathy pathogenesis and effects on the ageing and Alzheimer brain. Neurol Res 2003; 25: 611-16
54. Perry RH, Irving D, Blessed G, Fairbairn AF, Perry EK. Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci 1990; 95: 119-39
55. Mueckler M. Facilitative glucose transporters. Eur J Biochem 1994; 219: 713-25
56. Mai JK, Assheuer J, Paxinos G. Atlas of the Human Brain. San Diego: Academic Press, 1997
57. Wessel D, Flugge UI. A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal Biochem 1984; 138: 141-3
58. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000; 283: 1571-7
59. Court JA, Lloyd S, Thomas N, Piggott MA, Marshall EF, Morris CM, Lamb H, Perry RH, Johnson M, Perry EK. Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use. Neuroscience 1998; 87: 63-78
60. Nordberg A, Hellstrom-Lindahl E, Lee M, Johnson M, Mousavi M, Hall R, Perry E, Bednar I, Court J. Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw). J Neurochem 2002; 81: 655-8
61. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000; 408: 979-82
62. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000; 408: 982-5
63. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-7
64. Haugabook SJ, Le T, Yager D, Zenk B, Healy BM, Eckman EA, Prada C, Younkin L, Murphy P, Pinnix I, Onstead L, Sambamurti K, Golde TE, Dickson D, Younkin SG, Eckman CB. Reduction of Abeta accumulation in the Tg2576 animal model of Alzheimer's disease after oral administration of the phosphatidylinositol kinase inhibitor wortmannin. FASEB J 2001; 15: 16-18
65. Buxbaum JD, Geoghagen NS, Friedhoff LT. Cholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Abeta peptide. J Alzheimers Dis 2001; 3: 221-9
66. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001; 21: 8370-7
67. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, Bush AI. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001; 30: 665-76
68. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002; 298: 1379
69. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003; 9: 448-52
70. Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD, Danner S, Abramowski D, Sturchler-Pierrat C, Burki K, van Duinen SG, Maat-Schieman ML, Staufenbiel M, Mathews PM, Jucker M. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci 2004; 7: 954-60
71. Religa D, Laudon H, Styczynska M, Winblad B, Naslund J, Haroutunian V. Amyloid beta pathology in Alzheimer's disease and schizophrenia. Am J Psychiatry 2003; 160: 867-72
72. Beach TG, Kuo YM, Schwab C, Walker DG, Roher AE. Reduction of cortical amyloid beta levels in guinea pig brain after systemic administration of physostigmine. Neurosci Lett 2001; 310: 21-4
73. Coyle J, Kershaw P. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biol Psychiatry 2001; 49: 289-99
74. Kurz A, Erkinjuntti T, Small G, Lilienfeld S, Damaraju C. Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease. Eur J Neurol 2003; 10: 633-40
75. Perry EK, Kilford L, Lees AJ, Burn DJ, Perry RH. Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol 2003; 54: 235-8
76. Duelli R, Staudt R, Grunwald F, Kuschinsky W. Increase of glucose transporter densities (Glut1 and Glut3) during chronic administration of nicotine in rat brain. Brain Res 1998; 782: 36-42
77. Monteggia LM, Arneric SP, Giordano T. Nicotine effects on the regulation of amyloid precursor protein splicing, neurotrophin and glucose transporter RNA levels in aged rats. Int J Dev Neurosci 1994; 12: 133-41
78. Salomon AR, Marcinowski KJ, Friedland RP, Zagorski MG. Nicotine inhibits amyloid formation by the beta-peptide. Biochemistry 1996; 35: 13568-78
79. Ono K, Hasegawa K, Yamada M, Naiki H. Nicotine breaks down preformed Alzheimer's beta-amyloid fibrils in vitro. Biol Psychiatry 2002; 52: 880-6
80. Zeng H, Zhang Y, Peng L, Shao H, Menon NK, Yang J, Salomon AR, Freidland RP, Zagorski MG. Nicotine and amyloid formation. Biol Psychiatry 2001; 49: 248-57
81. Dickerson TJ, Janda KD. Glycation of the amyloid {beta}-protein by a nicotine metabolite: a fortuitous chemical dynamic between smoking and Alzheimer's disease. Proc Natl Acad Sci USA 2003; 18: 18
82. Benowitz NL, Jacob P. Nicotine metabolism in nonsmokers. Clin Pharmacol Ther 1990; 48: 473-4
83. Kim SH, Kim YK, Jeong SJ, Haass C, Kim YH, Suh YH. Enhanced release of secreted form of Alzheimer's amyloid precursor protein from PC12 cells by nicotine. Mol Pharmacol 1997; 52: 430-6
84. Pauly JR, Marks MJ, Gross SD, Collins AC. An autoradiographic analysis of cholinergic receptors in mouse brain after chronic nicotine treatment. J Pharmacol Exp Ther 1991; 258: 1127-36
85. Flores CM, Rogers SW, Pabreza LA, Wolfe BB, Kellar KJ. A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol 1992; 41: 31-7
86. Sanderson EM, Drasdo AL, McCrea K, Wonnacott S. Upregulation of nicotinic receptors following continuous infusion of nicotine is brain-region-specific. Brain Res 1993; 617: 349-52
87. Molinari EJ, Delbono O, Messi ML, Renganathan M, Arneric SP, Sullivan JP, Gopalakrishnan M. Up-regulation of human alpha7 nicotinic receptors by chronic treatment with activator and antagonist ligands. Eur J Pharmacol 1998; 347: 131-9
88. Benwell ME, Balfour DJ, Anderson JM. Evidence that tobacco smoking increases the density of (-)-[3H]nicotine binding sites in human brain. J Neurochem 1988; 50: 1243-7
89. Yates SL, Bencherif M, Fluhler EN, Lippiello PM. Up-regulation of nicotinic acetylcholine receptors following chronic exposure of rats to mainstream cigarette smoke or alpha 4 beta 2 receptors to nicotine. Biochem Pharmacol 1995; 50: 2001-8
90. Breese CR, Marks MJ, Logel J, Adams CE, Sullivan B, Collins AC, Leonard S. Effect of smoking history on [3H]nicotine binding in human postmortem brain. J Pharmacol Exp Ther 1997; 282: 7-13
91. Lukas RJ, Ke L, Bencherif M, Eisenhour CM. Regulation by nicotine of its own receptor. Drug Devel Res 1996; 38: 136-48
92. Collins AC, Marks M. Are nicotinic receptors activated or inhibited following chronic nicotine treatment? Drug Devel Res 1996; 38: 231-42
93. Buisson B, Bertrand D. Chronic exposure to nicotine upregulates the human (alpha) 4 (beta) 2 nicotinic acetylcholine receptor function. J Neurosci 2001; 21: 1819-29
94. Wang HY, Lee DH, Davis CB, Shank RP. Amyloid peptide Abeta (1-42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors. J Neurochem 2000; 75: 1155-61
95. Dineley KT, Bell KA, Bui D, Sweatt JD, Westerman M, Bell K, Ashe KH. Beta-Amyloid peptide activates alpha 7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Biol Chem 2002; 277: 25056-61
96. Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, Sweatt JD. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: in vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci 2001; 21:4125-33
97. Bednar I, Paterson D, Marutle A, Pham TM, Svedberg M, Hellstrom-Lindahl E, Mousavi M, Court J, Morris C, Perry E, Mohammed A, Zhang X, Nordberg A. Selective nicotinic receptor consequences in APP (SWE) transgenic mice. Mol Cell Neurosci 2002; 20: 354-65
98. Nagele RG, D'Andrea MR, Anderson WJ, Wang HY. Intracellular accumulation of beta-amyloid (1-42) in neurons is facilitated by the alpha7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience 2002; 110:199-211
99. Sharma G, Vijayaraghavan S. Nicotinic cholinergic signaling in hippocampal astrocytes involves calcium-induced calcium release from intracellular stores. Proc Natl Acad Sci USA 2001; 98: 4148-53
100. Teaktong T, Graham A, Court J, Perry R, Jaros E, Johnson M, Hall R, Perry E. Alzheimer's disease is associated with a selective increase in alpha7 nicotinic acetylcholine receptor immunoreactivity in astrocytes. Glia 2003;41:207-11
101. Giunta B, Ehrhart J, Townsend K, Sun N, Vendrame M, Shytle D, Tan J, Fernandez F. Galantamine and nicotine have a synergistic effect on inhibition of microglial activation induced by HIV-1 gp120. Brain Res Bull 2004; 64: 165-70
102. French SJ, Humby T, Horner CH, Sofroniew MV, Rattray M. Hippocampal neurotrophin and trk receptor mRNA levels are altered by local administration of nicotine, carbachol and pilocarpine. Brain Res Mol Brain Res 1999; 67: 124-36
103. Belluardo N, Blum M, Mudo G, Andbjer B, Fuxe K. Acute intermittent nicotine treatment produces regional increases of basic fibroblast growth factor messenger RNA and protein in the Tel- and diencephalon of the rat. Neuroscience 1998; 83: 723-40
104. Kenny PJ, File SE, Rattray M. Acute nicotine decreases, and chronic nicotine increases the expression of brain-derived neurotrophic factor mRNA in rat hippocampus. Brain Res Mol Brain Res 2000; 85: 234-8
105. Mattson MP, Tomaselli KJ, Rydel RE. Calcium-destabilizing and neurodegenerative effects of aggregated beta-amyloid peptide are attenuated by basic FGF. Brain Res 1993; 621: 35-49
106. Rossner S, Ueberham U, Schliebs R, Perez-Polo JR, Bigl V. Regulated secretion of amyloid precursor protein by TrkA receptor stimulation in rat pheochromocytoma-12 cells is mitogen activated protein kinase sensitive. Neurosci Lett 1999; 271: 97-100
107. Capsoni S, Ugolini G, Comparini A, Ruberti F, Berardi N, Cattaneo A. Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice. Proc Natl Acad Sci USA 2000; 97: 6826-31